Clinical trials: Tuberculosis
Tuberculosis, Multidrug Resistant
Drug Concentrations in the Treatment of MDR-TB Related to Minimum Inhibitory Concentrations
Multi-drug resistant tuberculosis (MDR-TB) is steadily increasing world-wide, urging for the need of improved treatment strategies.
- Trial name
- TDM-MDR-TB (NCT02816931)
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Karolinska Institutet
Lung Diseases, Tuberculosis
Behavioral Interventions for Control of TB
To compare alternative methods to ensure completion of treatment and preventive therapy for tuberculosis (TB) in inner cities, and to identify the most cost-effective methods to accomplish that.
- Trial name
- NCT00005739
- Testing
- Community-based directly observed therapy (DOT), Clinic directly observed therapy (DOT)
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- Columbia University
Pleural Effusion, Malignant Pleural Effusions
Quantitative C-Reactive Protein for Differentiating Tuberculous and Malignant Pleural Effusion: a Cross-Sectional Study
The goal of this observational study is to evaluate the role of pleural fluid Quantitative C-Reactive Protein (Q-CRP) levels in distinguishing between tuberculous and malignant pleural effusion in adult patients with lymphocytic…
- Conditions
- Pleural Effusion, Malignant Pleural Effusions, Tuberculous Pleural Effusion
- Trial name
- NCT06729931
- Testing
- Pleural Fluid Quantitative C-Reactive Protein (Q-CRP) Measurement
- Where
- Nepal
- Volunteers
- 81 people
- Sponsor
- Maharajgunj Medical Campus
Tuberculosis
The Effect of Telephone Follow-up and Training on Treatment Adherence in Tuberculosis Patients and Contacts
Tuberculosis (TB) is a preventable and curable disease mostly affecting lungs and caused by the bacteria called as Mycobacterium Tuberculosis (MTB).
- Trial name
- Tuberculosis (NCT05202431)
- Testing
- Treatment adherence
- Where
- Turkey (Türkiye)
- Volunteers
- 66 people
- Sponsor
- Tuberculosis Network European Trialsgroup
Tuberculosis
Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac
This study is a multicenter, double-blind, randomized, placebo-controlled Phase III trial designed to evaluate the efficacy and safety of the GamTBvac recombinant subunit tuberculosis vaccine for the prevention of active…
- Trial name
- NCT04975737
- Testing
- GamTBvac
- Where
- Russia
- Volunteers
- 9,500 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
COVID-19, Tuberculosis
Tuberculosis as a Risk Factor for a Worse Outcome Post-Sars-CoV-2 Infection
This study has two main objectives. First, the clinical characteristics and outcomes of hospitalized patients with symptomatic Covid-19 disease will be compared between persons with a history of past or current TB infection or…
- Conditions
- COVID-19, Tuberculosis, Post-acute COVID-19 Syndrome
- Trial name
- Co-TB (NCT05643781)
- Where
- South Africa
- Volunteers
- 157 people
- Sponsor
- The Aurum Institute NPC
Drug-Induced Acute Liver Injury, Tuberculosis (TB)
Silymarin Versus N-Acetylcysteine as Protective Effect Against Anti-tuberculosis Drugs Induced Liver Injury.
Worldwide, tuberculosis (TB) infection caused by Mycobacterium Tuberculosis, remains one of the top 10 deadly diseases having a significant socioeconomic burden in the world, especially in developing countries.
- Trial name
- NCT07875322
- Testing
- Antituberculosis drugs Group
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Assiut University
Tuberculosis
Study of GeneXpert Mycobacterium Tuberculosis/ Rifampicin (MTB/RIF) Versus the Routine Methods for Detection of Mycobacterium Tuberculosis
1. Compare the performance of GeneXpert method with the routine methods including smear microscopy and Lowenstein-Jensen (LJ) media culture to choose the best available test for the diagnosis of TB. 2.
- Trial name
- NCT06409572
- Testing
- GeneXpert MTB/RIF
- Volunteers
- 80 people
- Sponsor
- Sohag University
Tuberculosis, Pulmonary, Mycobacterium Tuberculous
Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali
Background: -Tuberculosis (TB) is an infection of the lungs caused by bacteria. In Mali, TB is diagnosed with a test that is fast and inexpensive but not always accurate.
- Conditions
- Tuberculosis, Pulmonary, Mycobacterium Tuberculous, Antitubercular Agents, Tuberculosis, Mulutidrug-Resistant
- Trial name
- NCT01381757
- Where
- 2 sites in United States, Mali
- Volunteers
- 34 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
A Home-Based Approach to Tuberculosis Preventive Treatment Management
Background: Tuberculosis (TB), though preventable and curable, remains a major public health concern worldwide. While elimination of tuberculosis infection (TBI) is critical to TB elimination, TBI continues to represent a…
- Trial name
- NCT07479030
- Testing
- A home-based approach to TB preventive treatment management
- Where
- Ethiopia
- Volunteers
- 1,300 people
- Sponsor
- Dilla University
Extrapulmonary Tuberculosis, Lymph Node Tuberculosis
Positron Emission Tomography in Extrapulmonary Tuberculosis
Tuberculosis (TB) remains a major public health problem. In extra-pulmonary forms, evidence of bacteriological cure is difficult to be obtained raising the need for other therapeutic assessment tools.
- Conditions
- Extrapulmonary Tuberculosis, Lymph Node Tuberculosis, Bone Tuberculosis
- Trial name
- TUBOGTEP (NCT01613196)
- Testing
- Positron Emission Tomography with 18F-Fluoro-deoxy-glucose
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Obesity, Tuberculosis
Effect of Weight and/or Obesity on Ethambutol Drug Concentrations
This study is designed to measure drug concentrations in the blood of healthy volunteers administered a single dose of ethambutol.
- Trial name
- NCT01048697
- Testing
- Ethambutol
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center
HIV Infections, Tuberculosis
A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV
Because drugs used to treat TB can reduce the amount of the anti-HIV drugs that reach the sites where the virus is located, this study is designed to see whether it is necessary to use higher doses of antiviral (anti-HIV) drugs…
- Trial name
- OPTI-NNRTI (NCT00523458)
- Testing
- efavirenz or nevirapine
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- Stanford University
Tuberculosis
Epidemiological Study In Tuberculosis-Endemic Urban Area in Senegal
A cross-sectional childhood M. tuberculosis infection survey of age-specific rates (defined by positivity to the test QuantiFERON-TB Gold Plus) will be conducted in Senegal to collect information on the local TB endemic to inform…
- Trial name
- MTBVAC-EPI (NCT03767946)
- Testing
- Quantiferon Gold Plus Test
- Where
- France
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Biomedical Research Center EPLS
Latent Tuberculosis
Implementation of an Integrated Care Strategy for Children Contacts of Patients With Tuberculosis
Introduction: childhood tuberculosis continues to be a major public health problem, despite the fact that the visibility of the epidemic in this population group has increased, studies are still lacking that can resolve the gaps…
- Trial name
- NCT04331262
- Where
- Colombia
- Volunteers
- 163 people
- Sponsor
- Corporacion para Investigaciones Biologicas
Lymphadenopathy, Lymphnode Metastasis
Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes
Lymph nodes are one of the most important components of the human immune system, and superficial lymph node enlargement lacks specificity.
- Conditions
- Lymphadenopathy, Lymphnode Metastasis, Lymphoma, Lymphatic Tuberculosis
- Trial name
- NCT07155954
- Testing
- SRUS imaging of the lymph nodes before surgery or biopsy
- Where
- China
- Volunteers
- 779 people
- Sponsor
- Peking University Third Hospital
HIV Infection, Tuberculosis
Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment
This study investigates the prevention of early mortality in patients initiating antiretroviral therapy (ART) in sub-Saharan Africa where 79% of the co-infected cases of TB reside.
- Trial name
- PrOMPT (NCT01417988)
- Testing
- Experimental: Empiric TB treatment, ART only arm
- Where
- 3 sites in Gabon, Mozambique and 1 more
- Volunteers
- 44 people
- Sponsor
- Prof JMA Lange
Tuberculosis
A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit Vaccine
The purpose of this study is to evaluate the safety profile of an adjuvanted TB subunit vaccine administered at 0 and 2 months in healthy BCG-unvaccinated volunteers with no prior history of TB disease or known prior exposure to…
- Trial name
- THYB-01 (NCT01003093)
- Testing
- 50 microgram antigen (Ag85B + ESAT-6), 50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a, 50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1a
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Tuberculosis, Pulmonary
Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)
Prospective, randomized, double-blind, multicentre, placebo-controlled clinical phase IIb trial to evaluate efficacy of RUTI® vaccine in DS- (Drug-Sensitive) and MDR-TB (Multidrug-resistant) patients favourably responding to…
- Trial name
- NCT04919239
- Testing
- RUTI®
- Where
- 2 sites in India
- Volunteers
- 140 people
- Sponsor
- Archivel Farma S.L.
Tuberculosis
Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent
The purpose of this study is to evaluate safety, immunogenicity of ID93+GLA-SE compared to placebo following three intramuscular (IM) injections on Days 0, 28 and 56 in BCG-vaccinated QFT-negative healthy adolescent.
- Trial name
- NCT03806699
- Testing
- ID93+GLA-SE
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Quratis Inc.